Literature DB >> 14660631

The role of phosphorylation in D1 dopamine receptor desensitization: evidence for a novel mechanism of arrestin association.

Ok-Jin Kim1, Benjamin R Gardner, Daniel B Williams, Paul S Marinec, David M Cabrera, Jennifer D Peters, Chun C Mak, Kyeong-Man Kim, David R Sibley.   

Abstract

Homologous desensitization of D(1) dopamine receptors is thought to occur through their phosphorylation leading to arrestin association which interdicts G protein coupling. In order to identify the relevant domains of receptor phosphorylation, and to determine how this leads to arrestin association, we created a series of mutated D(1) receptor constructs. In one mutant, all of the serine/threonine residues within the 3rd cytoplasmic domain were altered (3rdTOT). A second construct was created in which only three of these serines (serines 256, 258, and 259) were mutated (3rd234). We also created four truncation mutants of the carboxyl terminus (T347, T369, T394, and T404). All of these constructs were comparable with the wild-type receptor with respect to expression and adenylyl cyclase activation. In contrast, both of the 3rd loop mutants exhibited attenuated agonist-induced receptor phosphorylation that was correlated with an impaired desensitization response. Sequential truncation of the carboxyl terminus of the receptor resulted in a sequential loss of agonist-induced phosphorylation. No phosphorylation was observed with the most severely truncated T347 mutant. Surprisingly, all of the truncated receptors exhibited normal desensitization. The ability of the receptor constructs to promote arrestin association was evaluated using arrestin-green fluorescent protein translocation assays and confocal fluorescence microscopy. The 3rd234 mutant receptor was impaired in its ability to induce arrrestin translocation, whereas the T347 mutant was comparable with wild type. Our data suggest a model in which arrestin directly associates with the activated 3rd cytoplasmic domain in an agonist-dependent fashion; however, under basal conditions, this is sterically prevented by the carboxyl terminus of the receptor. Receptor activation promotes the sequential phosphorylation of residues, first within the carboxyl terminus and then the 3rd cytoplasmic loop, thereby dissociating these domains and allowing arrestin to bind to the activated 3rd loop. Thus, the role of receptor phosphorylation is to allow access of arrestin to its receptor binding domain rather than to create an arrestin binding site per se.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660631      PMCID: PMC4743542          DOI: 10.1074/jbc.M308281200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins.

Authors:  K M Kim; K J Valenzano; S R Robinson; W D Yao; L S Barak; M G Caron
Journal:  J Biol Chem       Date:  2001-07-25       Impact factor: 5.157

Review 2.  Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization.

Authors:  Trudy A Kohout; Robert J Lefkowitz
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

3.  Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases.

Authors:  M Tiberi; S R Nash; L Bertrand; R J Lefkowitz; M G Caron
Journal:  J Biol Chem       Date:  1996-02-16       Impact factor: 5.157

4.  Regulation of dopamine D(1) receptor trafficking by protein kinase A-dependent phosphorylation.

Authors:  John N Mason; Laura B Kozell; Kim A Neve
Journal:  Mol Pharmacol       Date:  2002-04       Impact factor: 4.436

5.  How does arrestin respond to the phosphorylated state of rhodopsin?

Authors:  S A Vishnivetskiy; C L Paz; C Schubert; J A Hirsch; P B Sigler; V V Gurevich
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

6.  High affinity agonist binding to the dopamine D3 receptor: chimeric receptors delineate a role for intracellular domains.

Authors:  S W Robinson; K R Jarvie; M G Caron
Journal:  Mol Pharmacol       Date:  1994-08       Impact factor: 4.436

7.  Use of simian virus 40 replication to amplify Epstein-Barr virus shuttle vectors in human cells.

Authors:  S S Heinzel; P J Krysan; M P Calos; R B DuBridge
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

8.  Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation.

Authors:  F J Monsma; L C Mahan; L D McVittie; C R Gerfen; D R Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

9.  Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells.

Authors:  A Kovoor; J Celver; R I Abdryashitov; C Chavkin; V V Gurevich
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

10.  Human substance P receptor lacking the C-terminal domain remains competent to desensitize and internalize.

Authors:  Mark D Richardson; Anastasia M Balius; Keisuke Yamaguchi; Emily R Freilich; Larry S Barak; Madan M Kwatra
Journal:  J Neurochem       Date:  2003-02       Impact factor: 5.372

View more
  38 in total

Review 1.  Cargo- and compartment-selective endocytic scaffold proteins.

Authors:  Iwona Szymkiewicz; Oleg Shupliakov; Ivan Dikic
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

2.  Dopamine D(3) receptors are down-regulated following heterologous endocytosis by a specific interaction with G protein-coupled receptor-associated sorting protein-1.

Authors:  Dawn Thompson; Jennifer L Whistler
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

3.  Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors.

Authors:  Jessica P Ryman-Rasmussen; Adam Griffith; Scott Oloff; Nagarajan Vaidehi; Justin T Brown; William A Goddard; Richard B Mailman
Journal:  Neuropharmacology       Date:  2006-10-24       Impact factor: 5.250

4.  The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation.

Authors:  Erika Peverelli; Giovanna Mantovani; Davide Calebiro; Andrea Doni; Sara Bondioni; Andrea Lania; Paolo Beck-Peccoz; Anna Spada
Journal:  Mol Endocrinol       Date:  2007-12-20

Review 5.  The structural basis of arrestin-mediated regulation of G-protein-coupled receptors.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Pharmacol Ther       Date:  2006-02-03       Impact factor: 12.310

6.  D1 dopamine receptor-mediated LTP at GABA synapses encodes motivation to self-administer cocaine in rats.

Authors:  Michal Krawczyk; Xenos Mason; Julian DeBacker; Robyn Sharma; Catherine P Normandeau; Emily R Hawken; Cynthia Di Prospero; Cindy Chiang; Audrey Martinez; Andrea A Jones; Évelyne Doudnikoff; Stephanie Caille; Erwan Bézard; François Georges; Éric C Dumont
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

7.  A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding.

Authors:  Hongxiang Lan; Yong Liu; Michal I Bell; Vsevolod V Gurevich; Kim A Neve
Journal:  Mol Pharmacol       Date:  2008-09-22       Impact factor: 4.436

Review 8.  The structural basis of the arrestin binding to GPCRs.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Mol Cell Endocrinol       Date:  2019-01-28       Impact factor: 4.102

9.  Reciprocal modulation of function between the D1 and D2 dopamine receptors and the Na+,K+-ATPase.

Authors:  Lisa A Hazelwood; R Benjamin Free; David M Cabrera; Mette Skinbjerg; David R Sibley
Journal:  J Biol Chem       Date:  2008-11-04       Impact factor: 5.157

10.  An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D2 and D3 receptors.

Authors:  Hongxiang Lan; Martha M Teeter; Vsevolod V Gurevich; Kim A Neve
Journal:  Mol Pharmacol       Date:  2008-09-26       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.